Another ASCO annual meeting has come and gone, and now comes the fun part where we digest and interpret the significance of the mountains of new data presented.
June 2015
The ASCO annual meeting has retained its core purpose of providing a unique platform for oncologists to interact and exchange the latest practice-changing research.
The past decade has demonstrated a movement toward more extensive LND in order to sample and remove more lymph nodes.
The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
Dr. Andre Goy discusses efforts to improve "compassionate use" programs that expand access to promising drugs that are not yet approved by the FDA.
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5